TFH lymphomas: the times they aza-changin'?

Blood. 2019 Oct 24;134(17):1364-1365. doi: 10.1182/blood.2019002806.

Abstract

In this issue of Blood, O’Connor and colleagues report a phase 1 study of romidepsin combined with oral azacytidine in patients with relapsed/refractory (R/R) lymphomas, including complete remissions among 3 patients with angioimmunoblastic T-cell lymphoma (AITL) and single patients with multiple other lymphoma subsets.

Publication types

  • Comment

MeSH terms

  • Azacitidine
  • Depsipeptides*
  • Humans
  • Lymphoma*
  • T-Lymphocytes, Helper-Inducer

Substances

  • Depsipeptides
  • romidepsin
  • Azacitidine